Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Profound Medical Corp (TSX: PRN )

11.60 +0.16 (+1.40%)
Streaming Delayed Price Updated: 9:56 AM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Profound Medical Corp

< Previous 1 2 Next >
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings 
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Third Quarter 2024 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Second Quarter 2024 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Annual General Meeting of Shareholders Voting Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
From Profound Medical Corp.
Via GlobeNewswire
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Non-Brokered Private Placement
From Profound Medical Corp.
Via GlobeNewswire
BioMedNewsBreaks – Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) Announces Pricing of US$20M Public Offering
Via Investor Brand Network
Exposures Product Safety
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Proposed Public Offering of Common Shares
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical to Participate in the Stifel 2023 Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting
From Profound Medical Corp.
Via GlobeNewswire
Profound Medical Announces Third Quarter 2023 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.